Hypoxia-Inducible Carbonic Anhydrase IX and XII Promote Tumor Cell Growth by Counteracting Acidosis through the Regulation of the Intracellular pH

2008 ◽  
Vol 69 (1) ◽  
pp. 358-368 ◽  
Author(s):  
Johanna Chiche ◽  
Karine Ilc ◽  
Julie Laferrière ◽  
Eric Trottier ◽  
Frédéric Dayan ◽  
...  
2004 ◽  
Vol 64 (17) ◽  
pp. 6160-6165 ◽  
Author(s):  
Naomi Robertson ◽  
Christian Potter ◽  
Adrian L. Harris

2013 ◽  
Vol 22 (23) ◽  
pp. 3114-3127 ◽  
Author(s):  
Katharina Mandel ◽  
Yuanyuan Yang ◽  
Axel Schambach ◽  
Silke Glage ◽  
Anna Otte ◽  
...  

2018 ◽  
Vol 217 (4) ◽  
pp. 1335-1351 ◽  
Author(s):  
Xiang Wang ◽  
Xiaofan Wei ◽  
Yang Yuan ◽  
Qingrui Sun ◽  
Jun Zhan ◽  
...  

FHL1 has been recognized for a long time as a tumor suppressor protein that associates with both the actin cytoskeleton and the transcriptional machinery. We present in this study a paradigm that phosphorylated FHL1 functions as an oncogenic protein by promoting tumor cell proliferation. The cytosolic tyrosine kinase Src interacts with and phosphorylates FHL1 at Y149 and Y272, which switches FHL1 from a tumor suppressor to a cell growth accelerator. Phosphorylated FHL1 translocates into the nucleus, where it binds to the transcription factor BCLAF1 and promotes tumor cell growth. Importantly, the phosphorylation of FHL1 is increased in tissues from lung adenocarcinoma patients despite the down-regulation of total FHL1 expression. Kindlin-2 was found to interact with FHL1 and recruit FHL1 to focal adhesions. Kindlin-2 competes with Src for binding to FHL1 and suppresses Src-mediated FHL1 phosphorylation. Collectively, we demonstrate that FHL1 can either suppress or promote tumor cell growth depending on the status of the sites for phosphorylation by Src.


2015 ◽  
Vol 4 (5) ◽  
pp. e1005460 ◽  
Author(s):  
Giulia Di Lullo ◽  
Magda Marcatti ◽  
Silvia Heltai ◽  
Emanuela Brunetto ◽  
Cristina Tresoldi ◽  
...  

1995 ◽  
Vol 36 (3) ◽  
pp. 611-621
Author(s):  
A Abe ◽  
N S Radin ◽  
J A Shayman ◽  
L L Wotring ◽  
R E Zipkin ◽  
...  

2021 ◽  
Vol 22 (11) ◽  
pp. 6098
Author(s):  
Ebru Temiz ◽  
Ismail Koyuncu ◽  
Mustafa Durgun ◽  
Murat Caglayan ◽  
Ataman Gonel ◽  
...  

Carbonic anhydrase IX (CAIX) is a hypoxia-related protein that plays a role in proliferation in solid tumours. However, how CAIX increases proliferation and metastasis in solid tumours is unclear. The objective of this study was to investigate how a synthetic CAIX inhibitor triggers apoptosis in the HeLa cell line. The intracellular effects of CAIX inhibition were determined with AO/EB, AnnexinV-PI, and γ-H2AX staining; measurements of intracellular pH (pHi), reactive oxygen species (ROS), and mitochondrial membrane potential (MMP); and analyses of cell cycle, apoptotic, and autophagic modulator gene expression (Bax, Bcl-2, caspase-3, caspase-8, caspase-9, caspase-12, Beclin, and LC3), caspase protein level (pro-caspase 3 and cleaved caspase-3, -8, -9), cleaved PARP activation, and CAIX protein level. Sulphonamide CAIX inhibitor E showed the lowest IC50 and the highest selectivity index in CAIX-positive HeLa cells. CAIX inhibition changed the morphology of HeLa cells and increased the ratio of apoptotic cells, dramatically disturbing the homeostasis of intracellular pHi, MMP and ROS levels. All these phenomena consequent to CA IX inhibition triggered apoptosis and autophagy in HeLa cells. Taken together, these results further endorse the previous findings that CAIX inhibitors represent an important therapeutic strategy, which is worth pursuing in different cancer types, considering that presently only one sulphonamide inhibitor, SLC-0111, has arrived in Phase Ib/II clinical trials as an antitumour/antimetastatic drug.


Author(s):  
Lori Holle ◽  
Labri Hicks ◽  
Wendy Song ◽  
Eric Holle ◽  
Thomas Wagner ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document